mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, Pradip K, Febbo, Phillip G, Bikoff, Rachel, Berger, Raanan, Xue, Qi, McMahon, Louis M, Manola, Judith, Brugarolas, James +5 more·2004·Nature Medicine
DOI 10.1038/nm1052

Cited by (962)

Items 201–300 of 962

  1. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor
    Dehong Yan, Adeleye Oluwatosin Adeshakin, Meichen Xu, Lukman Olalekan Afolabi, Guizhong Zhang, Youhai H. Chen, Xiaochun Wan · 2019 · Frontiers in Immunology
  2. Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
    Andrew J. Armstrong, Daniel J. George, Susan Halabi · 2012 · Journal of Clinical Oncology
  3. Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation
    Wolfgang Sieghart, Thorsten Fuereder, Katharina Schmid, Daniel Cejka, Johannes M. Werzowa, Fritz Wrba, Xiaowei Wang, Diego Gruber, Susanne Rasoul‐Rockenschaub, Markus Peck‐Radosavljevic et al. · 2007 · Transplantation
  4. AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation
    Han Tian, Rong Lian, Yun Li, Chenying Liu, Shujun Liang, Wei Li, Tianyu Tao, Xingui Wu, Yaokai Ye, Xia Yang et al. · 2020 · Nature Communications
  5. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
    Nicholas F. Brown, Maja Stefanović-Račić, IAN J. SIPULA, Germán Perdomo · 2007 · Metabolism
  6. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
    Andrew Erich Teschendorff, Sergio Gómez, Àlex Arenas, Dorraya El‐Ashry, Marcus Schmidt, Mathias C. Gehrmann, Carlos Caldas · 2010 · BMC Cancer
  7. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
    Debora Fumagalli, David Venet, Michail Ignatiadis, Hatem A. Azim, Marion Maetens, Françoise Rothé, Roberto Salgado, Ian Bradbury, Lajos Pusztai, Nadia Harbeck et al. · 2016 · JAMA Oncology
  8. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
    Justin Goodwin, Michael L. Neugent, Shin Yup Lee, Joshua H. Choe, Hyunsung Choi, Dana M. R. Jenkins, Robin J. Ruthenborg, Maddox W. Robinson, Ji Yun Jeong, Masaki Wake et al. · 2017 · Nature Communications
  9. Modulation of the Mammalian Target of Rapamycin Pathway by Diacylglycerol Kinase-produced Phosphatidic Acid
    Antonia Ávila‐Flores, Teresa Santos-Mendoza, Esther Rincón, Isabel Mérida · 2005 · Journal of Biological Chemistry
  10. Inhibition of Mammalian Target of Rapamycin Reverses Alveolar Epithelial Neoplasia Induced by Oncogenic K-ras
    Marie Wislez, Loreto Spencer, Julie G. Izzo, Denise M. Juroske, Kamna Singh Balhara, DIANNA DICKIE CODY, Roger E. Price, Walter N. Hittelman, Ignacio Ivan Wistuba, Jonathan M. Kurie · 2005 · Cancer Research
  11. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation
    Norie Yoshioka, Li Wang, Koji Kishimoto, Takanori Tsuji, Guo-fu Hu · 2006 · Proceedings of the National Academy of Sciences
  12. Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells
    Konstantinos G. Lasithiotakis, Tobias W. Sinnberg, Birgit Schittek, Keith T. Flaherty, Dagmar Kulms, Evelyn Maczey, Claus Garbe, Friedegund Elke Meier · 2008 · Journal of Investigative Dermatology
  13. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells
    Arifumi Iwamaru, Yasuko Kondo, Eiji Iwado, H Aoki, Keishi Fujiwara, Tomohisa Yokoyama, Gordon Brent Mills, Seiji Kondo · 2006 · Oncogene
  14. The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer
    Chitcholtan, Kenny, Sykes, Peter H, Evans, John J · 2012 · Journal of Translational Medicine
  15. Molecular targets for cancer chemoprevention
    William N. William, John Victor Heymach, Edward S. Kim, Scott Michael Lippman · 2009 · Nature Reviews Drug Discovery
  16. Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids
    Dario Barbone, Tsung‐Ming Yang, Jeffrey R. Morgan, Giovanni Gaudino, V. Courtney Broaddus · 2008 · Journal of Biological Chemistry
  17. The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
    Raushan T. Kurmasheva, Lorina Dudkin, Catherine A. Billups, Larisa V. Debelenko, Christopher L. Morton, Peter J. Houghton · 2009 · Cancer Research
  18. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells
    Yuhui Jiang, Yugang Wang, Ting Wang, David H. Hawke, Yanhua Zheng, Xinjian Li, Qin Zhou, Sadhan Majumder, Erfei Bi, David X. Liu et al. · 2014 · Nature Communications
  19. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
    Haiying Cheng, Marina Shcherba, Gopichand Pendurti, Yuanxin Liang, Bilal Piperdi, Roman Perez-Soler · 2014 · Lung Cancer Management
  20. (Aryloxyacetylamino)benzoic Acid Analogues: A New Class of Hypoxia-Inducible Factor-1 Inhibitors
    Kyeong Lee, Jeong Hyun Lee, Shanthaveerappa K. Boovanahalli, Yinglan Jin, Mijeoung Lee, Xuejun Jin, Jin Hwan Kim, Young‐Soo Hong, Jung Joon Lee · 2007 · Journal of Medicinal Chemistry
  21. Metformin targets c-MYC oncogene to prevent prostate cancer
    Tunde O. Akinyeke, Satoko Matsumura, Xinying Wang, Yingjie Wu, Eric D. Schalfer, Anjana D. Saxena, Wenbo Yan, Susan K. Logan, Xin Li · 2013 · Carcinogenesis
  22. Management of toxicity to isoform α-specific PI3K inhibitors
    Nunnery, S.E., Mayer, I.A. · 2019 · Annals of Oncology
  23. Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
    Nageatte Ibrahim, Frank G. Haluska · 2008 · Annual Review of Pathology Mechanisms of Disease
  24. Mitochondrial function and glucose metabolism in the placenta with gestational diabetes mellitus: role of miR-143
    Sribalasubashini Muralimanoharan, Alina Maloyan, Leslie Myatt · 2016 · Clinical Science
  25. Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis
    Iga · 1992 · International Journal of Oncology
  26. AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer
    Carmen Priolo, Saumyadipta Pyne, J.A. Rose, Erzsébet Ravasz Regan, Giorgia Zadra, Cornelia Photopoulos, Stefano Cacciatore, Denise Schultz, Natalia Scaglia, Jonathan E. McDunn et al. · 2014 · Cancer Research
  27. Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
    Shuyang Chen, Nianli Sang · 2015 · Journal of Cellular Biochemistry
  28. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
    Bingshe Han, Dongkyoo Park, Rui Li, Maohua Xie, Taofeek Kunle Owonikoko, Guojing Zhang, Gabriel Sica, Chunyong Ding, Jia Zhou, Andrew T. Magis et al. · 2015 · Cancer Cell
  29. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis
    Jiao Zhang, Yanhong Yao, Baoguo Li, Qing Yang, Peng-Yu Zhang, Hai-Tao Wang · 2015 · Scientific Reports
  30. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
    Hung The Huynh, Pierce K. H. Chow, Khee Chee Soo, Han Chong Toh, Su Pin Choo, Kian Fong Foo, Donald Y. H. Poon, Van Chanh Ngo, Evelyn Tran · 2008 · Journal of Cellular and Molecular Medicine
  31. Malignancies in renal transplantation: an unmet medical need
    Jacques Dantal, Erich Pohanka · 2007 · Nephrology Dialysis Transplantation
  32. A multivariate approach for integrating genome-wide expression data and biological knowledge
    Sek Won Kong, William T. Pu, Peter J. Park · 2006 · Bioinformatics
  33. AKT Signaling in Physiology and Disease
    Krishna Murthi Vasudevan, Levi A. Garraway · 2010 · Current topics in microbiology and immunology
  34. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
    Michael Thomas Schweizer, Kathleen L. Haugk, Jožefa S. McKiernan, Roman Gulati, Heather H. Cheng, Jessica L. Maes, Ruth F. Dumpit, Peter S. Nelson, Bruce Montgomery, Jeannine S. McCune et al. · 2018 · PLoS ONE
  35. Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
    Arnoud J. Templeton, Valérie Dutoit, Richard L. Cathomas, Christian Alexander Rothermundt, Daniela Bärtschi, C. Droege, Oliver Pascal Gautschi, Markus Borner, Eva Fechter, Frank Stenner et al. · 2013 · European Urology
  36. Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells
    Todd W. Miller, James T. Forbes, Chirayu Shah, Shelby K. Wyatt, H. Charles Manning, Maria Graciela Olivares, Violeta M. Sanchez, Teresa C. Dugger, Nara de Matos Granja, Archana Narasanna et al. · 2009 · Clinical Cancer Research
  37. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment
    Olga Frolova, Ismael J. Samudio, Juliana Maria Benito, Rodrigo Omar Jacamo, Steven Mitchell Kornblau, Ana Karković Marković, Wendy D. Schober, Hongbo Lu, Yi Hua Qiu, Daniela Buglio et al. · 2012 · Cancer Biology & Therapy
  38. Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer
    Irwin Leav, Janet Plescia, Hira Lal Goel, Jing Li, Zhong Jiang, Ronald J. Cohen, Lucia Raffaella Languino, Dario C. Altieri · 2009 · American Journal Of Pathology
  39. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
    Gunnar Johansson, Yonatan Y. Mahller, Margaret H. Collins, Mi‐Ok Kim, Takahiro Nobukuni, John Peter Perentesis, Timothy P. Cripe, Heidi A. Lane, Sara C. Kozma, George Thomas et al. · 2008 · Molecular Cancer Therapeutics
  40. The Biological Role of PI3K Pathway in Lung Cancer
    Evangelos Sarris, Muhammad Wasif Saif, Kostas Syrigos · 2012 · Pharmaceuticals
  41. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
    Hisao Imai, Kyoichi Kaira, Noboru Oriuchi, Kimihiro Shimizu, Hideyuki Tominaga, Noriko Yanagitani, Noriaki Sunaga, Tamotsu Ishizuka, Shushi Nagamori, Kanyarat Promchan et al. · 2010 · PubMed
  42. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma
    Sally K. Martin, Peter Diamond, Stan Gronthos, Daniel J. Peet, Andrew C.W. Zannettino · 2011 · Leukemia
  43. Immune Infiltration in Invasive Lobular Breast Cancer
    Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert Van den Eynden, Gabriele M. Zoppoli, Françoise Rothé, Laurence Buisseret, Soizic Garaud, Karen E Willard-Gallo et al. · 2017 · JNCI Journal of the National Cancer Institute
  44. Monitoring cancer treatment with PET/CT: does it make a difference?
    Wolfgang Weber, Robert A. Figlin · 2007 · PubMed
  45. Everolimus
    Jens Hasskarl · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  46. Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression
    Chia‐Hsin Chan, Szu-Wei Lee, Jing Wang, Hui-Kuan Lin · 2010 · The Scientific World JOURNAL
  47. Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors
    Jingxiang Huang, Shulin Wu, Chin‐Lee Wu, Brendan D. Manning · 2009 · Cancer Research
  48. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication
    Clodagh C. O’Shea, Kristina Klupsch, Serah Choi, Bridget Bagus, Conrado T. Soria, Jerry Shen, Frank P. McCormick, David Stokoe · 2005 · The EMBO Journal
  49. 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
    Nicolaos Jay Palaskas, Steven M. Larson, Nikolaus D. Schultz, Evangelia Komisopoulou, Justin Wong, Daniel Rohle, Carl Campos, Nicolas A. Yannuzzi, Joseph R. Osborne, Irina Linkov et al. · 2011 · Cancer Research
  50. Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy
    Kaiyuan Ni, Guangxu Lan, Yang Song, Ziyang Hao, Wenbin Lin · 2020 · Chemical Science
  51. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
    Jorge Alberto Garcia, David Danielpour · 2008 · Molecular Cancer Therapeutics
  52. Development of novel therapeutic strategies that target HIF-1
    Gregg L. Semenza · 2006 · Expert Opinion on Therapeutic Targets
  53. Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies
    David Barrett, Valerie I. Brown, Stephan A. Grupp, David T. Teachey · 2012 · Pediatric Drugs
  54. Real-Time Imaging of HIF-1α Stabilization and Degradation
    Ekaterina Moroz, Sean Carlin, Katerina Dyomina, Sean A. Burke, Howard T. Thaler, Ronald Blasberg, Inna S. Serganova · 2009 · PLoS ONE
  55. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma
    Joseph Thaddeus Beck, Amen Ismail, Christina Tolomeo · 2014 · Cancer Treatment Reviews
  56. Hypoxia inducible factor-1: a novel target for cancer therapy
    Vladimir E. Belozerov, Erwin G. Van Meir · 2005 · Anti-Cancer Drugs
  57. The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
    Ivana Božović‐Spasojević, Dimitrios Zardavas, Sylvain Brohée, Lieveke Ameye, Debora Fumagalli, Felipe Ades, Evandro de Azambuja, Yacine Barèche, Martine J Piccart, Marianne Paesmans et al. · 2016 · Clinical Cancer Research
  58. The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model
    John C. Mavropoulos, W. Cooper Buschemeyer, Alok K. Tewari, Dmitriy Rokhfeld, Michaël Pollak, Yunhua Zhao, Phillip G. Febbo, Pinchas Cohen, David Hwang, Gayathri R. Devi et al. · 2009 · Cancer Prevention Research
  59. Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells
    Christopher F. MacManus, Johanna Pettigrew, Angela Seaton, Catherine Wilson, Pamela J. Maxwell, Silvia Berlingeri, Colin Purcell, Maryalice McGurk, Patrick G. Johnston, David J J Waugh · 2007 · Molecular Cancer Research
  60. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer
    W Du, S Wang, Qian Zhou, Xiaoxing Li, J Chu, Zai Chang, Qian Tao, Enders K. O. Ng, Jing‐Yuan Fang, Joseph J.�Y. Sung et al. · 2012 · Oncogene
  61. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice
    Shi H, Dan Li, Jing Zhang, Yongsheng Wang, Yang Li, Hai‐long Zhang, Xianhuo Wang, Bo Mu, Wei Wang, Yu Ma et al. · 2010 · Cancer Science
  62. The mTORC2 signaling network: targets and cross-talks
    Aparna Ragupathi, Christian Kim, Estela Jacinto · 2024 · Biochemical Journal
  63. PI3K inhibitors for cancer treatment: where do we stand?
    Sauveur-Michel Maira, Frédéric Stauffer, Christian Schnell, Carlos Garcı́a-Echeverrı́a · 2009 · Biochemical Society Transactions
  64. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis
    Hendrik Seeliger, Markus Otto Guba, Axel Kleespies, Karl‐Walter Jauch, Christiane J. Bruns · 2007 · Cancer and Metastasis Reviews
  65. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2
    Mohd Askandar Iqbal, Farid Ahmad Siddiqui, Vibhor Gupta, Shilpi Chattopadhyay, Gopinath Prakasam, Bhupender Kumar, Siddharth Manvati, Noor Chaman, Ramesh N K Bamezai · 2013 · Molecular Cancer
  66. Mouse models of prostate cancer: picking the best model for the question
    Magdalena M. Grabowska, David J. DeGraff, Xiuping Yu, Ren Jie Jin, Zhenbang Chen, Alexander D. Borowsky, Robert J. Matusik · 2014 · Cancer and Metastasis Reviews
  67. The regulatory roles of phosphatases in cancer
    Justin Stebbing, Lei Cheng Lit, Hengshuo Zhang, R. Siobhan Darrington, Ombretta Melaiu, Bharath Rudraraju, Georgios Giamas · 2013 · Oncogene
  68. Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells
    Alexander A. Goldberg, Adam Beach, Gerald F. Davies, Troy A. A. Harkness, Andrea Claire LeBlanc, Vladimir I. Titorenko · 2011 · Oncotarget
  69. Combined Bcl-2/Mammalian Target of Rapamycin Inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non–Small Cell Lung Tumor Xenograft Model
    Kwang Woon Kim, Luigi Moretti, Lauren Mitchell, Dae Kwang Jung, Jiahong Lu · 2009 · Clinical Cancer Research
  70. Metabolism Is Central to Tolerogenic Dendritic Cell Function
    Wen Jing Sim, Patricia Jennifer Ahl, John Edward Connolly · 2016 · Mediators of Inflammation
  71. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
    David T. Teachey, Stephan A. Grupp, Valerie I. Brown · 2009 · British Journal of Haematology
  72. mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process
    Sulaiman K. Marafie, Fahd Al‐Mulla, Jehad Ahmed Abubaker · 2024 · International Journal of Molecular Sciences
  73. Cancer‐like metabolism of the mammalian retina
    Soo Khai Ng, John PM Wood, Glyn Chidlow, Guoge Han, Thaksaon Kittipassorn, Daniel J. Peet, Robert James Casson · 2014 · Clinical and Experimental Ophthalmology
  74. Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient
    Brian I. Rini · 2009 · Journal of Clinical Oncology
  75. Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management
    Yingmei Zhang, Adam T. Whaley‐Connell, James R. Sowers, Jun Tao Ren · 2018 · Pharmacology & Therapeutics
  76. Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer
    Philipp C. Manegold, Carmen Paringer, Ulrike Kulka, Klaus Krimmel, Martin Eichhorn, Ralf Wilkowski, Karl‐Walter Jauch, Markus Otto Guba, Christiane J. Bruns · 2008 · Clinical Cancer Research
  77. K63-Linked Ubiquitination in Kinase Activation and Cancer
    Guocan Wang, Yuan Gao, Li Li, Guoxiang Jin, Zhen Cai, Jui I. Chao, Hui-Kuan Lin · 2012 · Frontiers in Oncology
  78. Inactivation of Pten in Osteo-Chondroprogenitor Cells Leads to Epiphyseal Growth Plate Abnormalities and Skeletal Overgrowth
    Alice Fiona Ford-Hutchinson, Zenobia Ali, Suzen Elizabeth Lines, Benedikt Hallgrímsson, Steven K. Boyd, Frank Robert Jirik · 2007 · Journal of Bone and Mineral Research
  79. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo
    Pu Shi, Suhaas Rayudu Aluri, Yi‐An Lin, Mihir S. Shah, Maria C. Edman, Jugal P. Dhandhukia, Honggang Cui, John Andrew MacKay · 2013 · Journal of Controlled Release
  80. Targeting LKB1 signaling in cancer
    Susanne E. Korsse, Maikel Petrus Peppelenbosch, Wendy van Veelen · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  81. Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity
    Samuel Martins Gonçalves, Cláudio Duarte‐Oliveira, Cláudia F. Campos, Vishukumar Aimanianda, Rob ter Horst, Luis Leite, Toine Mercier, Paulo N. G. Pereira, Miguel Fernández-García, Daniela Antunes et al. · 2020 · Nature Communications
  82. Cellular and molecular effects of the mTOR inhibitor everolimus
    Uttara Saran, Michelangelo Foti, Jean‐François Dufour · 2015 · Clinical Science
  83. Molecular Imaging in the Development of Cancer Therapeutics
    Johannes G. Czernin, Wolfgang Weber, Harvey R. Herschman · 2006 · Annual Review of Medicine
  84. Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas
    François-Xavier Picault, Carline Chaves-Almagro, Fabrice Projetti, Hervé Prats, Bernard Masri, Yves Audigier · 2013 · European Journal of Cancer
  85. The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells
    Vesna Cerovac, Jose Luis Monteserin Garcia, Hadara Rubinfeld, Michael Buchfelder, Marco Losa, Tullio Florio, Marcelo Páez-Pereda, Günter Karl Stalla, Marily Theodoropoulou · 2010 · Cancer Research
  86. Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice
    Dhwanil A. Dalwadi, Laura Torrens, Jordi Abril‐Fornaguera, Roser Pinyol, Catherine E. Willoughby, Jeffrey Posey, Josep Maria Llovet, Christian Lanciault, David W. Russell, Markus Grompe et al. · 2020 · Molecular Therapy
  87. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells
    Chengfu Zhou, Xuebing Li, Heng Sun, Bo Zhang, Yusong Han, Yi Jiang, Qiulin Zhuang, Jing Susan Fang, Guohao Wu · 2012 · IUBMB Life
  88. Targeting prostate cancer based on signal transduction and cell cycle pathways
    John Tayu Lee, Brian David Lehmann, David M. Terrian, William H. Chappell, Franca Stivala, Massimo Libra, Alberto Maria Martelli, Linda S. Steelman, James Andrew McCubrey · 2008 · Cell Cycle
  89. ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis
    Xuesong Liu, Jenna E. Haines, Elie K. Mehanna, MATTHEW D. GENET, Issam Ben‐Sahra, John M. Asara, Brendan D. Manning, Zhi-Min Yuan · 2014 · Genes & Development
  90. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
    Thomas B. Powles, Matthew James Wheater, Omar Sadeeq Din, T. Geldart, Ekaterini Boleti, Andrew D. Stockdale, Santhanam Sundar, Angus Robinson, Imtiaz Ahmed, Akhila Ganeshi Wimalasingham et al. · 2015 · European Urology
  91. Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin
    CRISTIANE HELENA SQUARIZE, ROGERIO MORAES CASTILHO, Jorge Silvio Gutkind · 2008 · Cancer Research
  92. Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer
    Simona Nanni, Carmen Priolo, Annalisa Grasselli, Manuela D’Eletto, Roberta Merola, Fabiola Moretti, Michele Gallucci, Piero De Carli, Steno Sentinelli, Anna Maria Cianciulli et al. · 2006 · Molecular Cancer Research
  93. Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin
    Mohd Askandar Iqbal, Ramesh N K Bamezai · 2012 · PLoS ONE
  94. A Hexane Fraction of Guava Leaves ( Psidium guajava L.) Induces Anticancer Activity by Suppressing AKT/Mammalian Target of Rapamycin/Ribosomal p70 S6 Kinase in Human Prostate Cancer Cells
    Nae Hyung Ryu, Kyung‐Ran Park, Sung‐Moo Kim, Hyung‐Mun Yun, Dongwoo Nam, Seok‐Geun Lee, Hyeung-Jin Jang, Kyoo Seok Ahn, Sung‐Hoon Kim, Bum Sang Shim et al. · 2012 · Journal of Medicinal Food
  95. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress
    Brittany Dewdney, Misty Rayna Jenkins, Sarah A. Best, Saskia Freytag, Krishneel Prasad, Jeff Holst, Raelene Endersby, Terrance G. Johns · 2023 · Signal Transduction and Targeted Therapy
  96. Hypoxia-Inducible Factor Directs POMC Gene to Mediate Hypothalamic Glucose Sensing and Energy Balance Regulation
    Hai Zhang, Guo Zhang, Frank J. Gonzalez, Sung-min Park, Dongsheng Cai · 2011 · PLoS Biology
  97. Predicted mechanisms of resistance to mTOR inhibitors
    Raushan T. Kurmasheva, Shile Huang, Peter J. Houghton · 2006 · British Journal of Cancer
  98. Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?
    Marco Tafani, Bruna Pucci, Andrea Russo, Luana Schito, Laura Pellegrini, Giulietta Anna Perrone, Lidia Villanova, Luisa Salvatori, Linda Ravenna, Elisa Petrangeli et al. · 2013 · Frontiers in Pharmacology
  99. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance
    Deyin Xing, Sandra Oršulić · 2005 · Proceedings of the National Academy of Sciences
  100. Transcriptional regulation of the stress response by mTOR
    Jose F. Aramburu, M. Carmen Ortells, Sonia Tejedor Vaquero, Maria Buxadé, Cristina López‐Rodríguez · 2014 · Science Signaling